

**B–helper neutrophils stimulate immunoglobulin diversification and production in the marginal zone of the spleen**

**Irene Puga, Montserrat Cols, Carolina M. Barra, Bing He, Linda Cassis, Maurizio Gentile, Laura Comerma, Alejo Chorny, Meimei Shan, Weifeng Xu, Giuliana Magri, Daniel M. Knowles, Wayne Tam, April Chiu, James B Bussel, Sergi Serrano, José Antonio Lorente, Beatriz Bellosillo, Josep Lloreta, Nuria Juanpere, Francesc Alameda, Teresa Baró, Cristina Díaz de Heredia, Núria Torán, Albert Català, Montserrat Torreadell, Claudia Fortuny, Victoria Cusí, Carmen Carreras, George A. Diaz, J. Magarian Blander, Claire-Michele Farber, Guido Silvestri, Charlotte Cunningham-Rundles, Michaela Calvillo, Carlo Dufour, Lucia Notarangelo, Vassilios Lougaris, Alessandro Plebani, Jean-Laurent Casanova, Stephanie C. Ganal, Andreas Diefenbach, Juan Ignacio Aróstegui, Manel Juan, Jordi Yagüe, Nizar Mahlaoui, Jean Donadieu, Kang Chen & Andrea Cerutti**

**SUPPLEMENTARY TABLES S1 – S6**

**SUPPLEMENTARY FIGURES AND LEGENDS S1 – S22**

**SUPPLEMENTARY MOVIE LEGENDS M1 and M2**

## SUPPLEMENTARY TABLES

Table S1. Patients with neutrophil disorders.

Sex	Age	Immunodeficiency	Gene mutated	(mg/dL)		
				IgA <sup>¶</sup>	IgG	IgM
M	11 yr	SCN <sup>#</sup>	Unknown	378,3	418,1	117,3
F	11 yr	SCN	Unknown	184,1	1179,5	273,1
F	14 yr	SCN	Unknown	116,2	691,5	166,2
F	15 yr	SCN	Unknown	174,3	961,9	158,2
F	16 yr	SCN	Unknown	204,7	889,2	220,4
F	19 yr	SCN	Unknown	11,3	187,2	42,4
F	32 yr	SCN	Unknown	186,8	479,2	167,3
F	35 yr	SCN	Unknown	388,4	1770,3	242,6
F	36 yr	SCN	Unknown	273,4	479,2	108,1
F	41 yr	SCN	Unknown	N/A*	N/A	N/A
M	49 yr	SCN	Unknown	246,5	604,2	225,0
M	50 yr	SCN	Unknown	326,4	1744,1	153,2
M	17 yr	SCN	<i>ELANE</i>	467,9	2063,1	197,1
M	10 yr	SCN	<i>ELANE</i>	N/A	N/A	N/A
M	12 yr	SCN	<i>WAS</i>	405,6	1712,1	245,3
M	14 yr	SBDS <sup>##</sup>	<i>SBDSP1</i>	305,7	1302,1	119,2
F	19 yr	SBDS <sup>##</sup>	<i>SBDSP1</i>	65,1	95,3	88,2
F	N/A	WHIM <sup>§</sup> syndrome	<i>CXCR4</i>	188,7	1267,2	68,0
F	N/A	WHIM syndrome	<i>CXCR4</i>	70,2	176,8	60,4
F	24 yr	CN <sup>¥</sup>	<i>ELANE</i>	452,8	1848,8	265,9
F	27 yr	CGD <sup>□</sup>	<i>CYBB</i>	281,6	819,4	262,1
F	12 yr	LAD-1 <sup>°</sup>	<i>ITGB2</i>	340,5	1159,6	175,0

<sup>¶</sup>Normal range IgA [142-262]; IgG [920-1480]; IgM [88-184].

<sup>#</sup>SCN, severe congenital neutropenia (< 500 neutrophils/ $\mu$ l).

\*N/A, not available.

<sup>##</sup>SBDS, Shwachman-Bodian-Diamond syndrome (< 500 neutrophils/ $\mu$ l).

<sup>§</sup>WHIM, warts-hypogammaglobulinemia-infections-myelokathexis syndrome (< 500 neutrophils/ $\mu$ l).

<sup>¥</sup>CN, cyclic neutropenia (< 1000 neutrophils/ $\mu$ l).

<sup>□</sup>CGD, chronic granulomatous disease (> 1500 neutrophils/ $\mu$ l).

<sup>°</sup>LAD-1, leukocyte adhesion deficiency-1 (> 1500 neutrophils/ $\mu$ l).

**Table S2. Fresh tissue samples.**

<b>SAMPLE</b>	<b>SEX</b>	<b>AGE</b>	<b>CONDITION</b>
Spleen	M	4 yr	Organ donor
Spleen	M	22 yr	Organ donor
Spleen	F	51 yr	Organ donor
Spleen	M	56 yr	Organ donor
Spleen	F	58 yr	Organ donor
Spleen	F	62 yr	Organ donor
Spleen	F	68 yr	Organ donor
Spleen	F	68 yr	Organ donor
Spleen	F	68 yr	Organ donor
Spleen	M	74 yr	Organ donor
Spleen	F	78 yr	Organ donor
Spleen	F	86 yr	Organ donor
Spleen	F	71 yr	Organ donor
Spleen	M	12 yr	Trauma
Spleen	M	22 yr	Trauma
Spleen	M	22 yr	Trauma
Spleen	M	34 yr	Trauma
Spleen	F	35 yr	Trauma
Spleen	F	43 yr	Trauma
Spleen	M	44 yr	Trauma
Spleen	M	48 yr	Trauma
Spleen	F	55 yr	Trauma
Spleen	F	57 yr	Trauma
Spleen	F	59 yr	Trauma
Spleen	N/A*	N/A	SCN <sup>#</sup>
Axilar lymph node	F	49 yr	Breast cancer
Pelvic lymph node	F	73 yr	Squamous cell carcinoma
Retroperitoneal lymph node	F	68 yr	Organ donor
Mesenteric lymph node	N/A	N/A	Colon carcinoma
Mesenteric lymph node	N/A	N/A	Colon carcinoma
Tonsils	F	7 yr	Follicular hyperplasia
Tonsils	F	9 yr	Follicular hyperplasia

\*Not available.

<sup>#</sup>SCN, severe congenital neutropenia

**Table S3. Frozen and paraffin-embedded tissue samples.**

<b>SAMPLE</b>	<b>SEX</b>	<b>AGE</b>	<b>CONDITION</b>
Fetal spleen		12 wk	Induced abortion
Fetal spleen		17,5 wk	Spontaneous abortion
Fetal spleen		19 wk	Spontaneous abortion
Fetal spleen		20 wk	Induced abortion
Fetal spleen		21 wk	Induced abortion
Fetal spleen		21 wk	Induced abortion
Fetal spleen		21 wk	Induced abortion
Fetal spleen		22 wk	Induced abortion
Fetal spleen		22 wk	Spontaneous abortion
Fetal spleen		22 wk	Induced abortion
Fetal spleen		32 wk	Spontaneous abortion
Fetal spleen		41 wk	Spontaneous abortion
Neonatal spleen	M	2 d	Congenital cardiopathy
Neonatal spleen	F	10 d	Diaphragmatic hernia
Neonatal spleen	M	30 d	Microangiopathy
Neonatal spleen	M	6 mo	Cardiopathy
Spleen	M	4 yr	Trauma
Spleen	M	6 yr	Brain aneurysm
Spleen	F	14 yr	N/A*
Spleen	F	35 yr	Trauma
Spleen	M	70 yr	Trauma
Spleen	M	58 yr	Colon cancer
Spleen	N/A	N/A	Bleeding disorder
Spleen	N/A	N/A	Systemic lupus erythematosus
Spleen	N/A	N/A	Systemic lupus erythematosus
Spleen	N/A	N/A	HIV infection
Spleen	N/A	N/A	Hereditary spherocytosis
Spleen	N/A	N/A	Severe congenital neutropenia
Spleen	N/A	N/A	Hyper-IgD syndrome
Spleen	F	31 yr	Idiopathic thrombocytopenic purpura
Spleen	M	72 yr	Idiopathic thrombocytopenic purpura
Intestine	M	83 yr	Colon cancer
Intestine	M	67 yr	Colon cancer
Intestine	M	84 yr	Colon cancer
Mesenteric lymph node	M	74 yr	Colon cancer
Mesenteric lymph node	M	49 yr	Colon cancer
Cervical lymph node	F	30 yr	Thyroid cancer
Cervical lymph node	F	30 yr	Thyroid cancer
Cervical lymph node	M	54 yr	Laryngeal cancer
Axillar lymph node	F	49 yr	Breast cancer
Pelvic lymph node	F	68 yr	Prostate cancer
Pelvic lymph node	F	73 yr	Prostate cancer
Tonsils	F	9 yr	Follicular hyperplasia
Tonsils	M	6 yr	Follicular hyperplasia

\*Not available.

**Table S4. Antibodies used in flow cytometry and immunofluorescence.****a. Antibodies to human antigens.**

<b>Antigen</b>	<b>Label</b>	<b>Isotype</b>	<b>Clone (if monoclonal)</b>	<b>Manufacturer</b>	<b>Use</b>
AID		Rat IgG2b	EK2 5G9	Cell Signaling	<sup>1</sup> IF
AID		Goat IgG	-	Santa Cruz	
APRIL		Rabbit IgG	ED2	Prosci	<sup>#</sup> FC /IF
BAFF		Mouse IgG1	1D6	eBioscience	IF
BAFF	PE	Mouse IgG1	1D6	eBioscience	
CD8	FITC	Mouse IgG1	RFT-8	Southern Biotech	FC
CD11b	PE	Mouse-IgG2a	D12	BD Biosciences	FC
CD11c	PE	Mouse IgG1	B-ly6	BD Biosciences	IF
CD15	FITC	Mouse IgM	28	Southern Biotech	FC
CD15	Biotin	Mouse IgG1	W6D3	Biologend	
CD15		Mouse IgM	28	Southern Biotech	IF
CD16	Biotin	Mouse IgG1	3G8	BD Biosciences	FC
CD16	PE	Mouse IgG1	3G8	BD Biosciences	FC
CD16	Alexa647	Mouse IgG1	3G8	BD Biosciences	
CD19	APC	Mouse IgG1	H1B19	BD Biosciences	
CD19	PE-Cy7	Mouse IgG1	H1B19	Biologend	FC
CD20	FITC	Mouse IgG1	L27	BD Biosciences	*IHC
CD24	PE	Mouse IgG2a	ML5	BD Biosciences	FC
CD27	PE	Mouse IgG1	M-T271	Ancell	FC
CD31	PE	Mouse IgG1	TDR31.3	Ancell	
CD31	Alexa 647	Mouse IgG2a	M89D3	BD Biosciences	
CD31		Mouse IgG1	M0823	Dako	IF
CD38	PE	Mouse IgG1	HIT2	BD Biosciences	FC
CD54	PE	Mouse IgG1	HCD54	Biologend	FC
CD62L	PE-Cy7	Mouse IgG1	DREG-56	eBioscience	FC
CD62P	PE	Mouse IgG1	AK4	Biologend	FC
CD68		Mouse IgG1	KP1	Dako	IF
CD86	PE	Mouse IgG2b	IT2.2 BD	Biosciences	FC
CD95	PE	Mouse IgG1	DX2	BD Biosciences	FC
CD102	PE	Mouse IgG1	CBR-IC2/2	Biologend	FC
CD154 (CD40L)	PE	Mouse IgG1	24-31	Ancell	FC
CD163		Mouse IgG1	10D6	Thermo Scientific	IF
CD206 (MR)		Mouse IgG1	19.2	BD Biosciences	IF
CD206 (MR)	FITC	Mouse IgG1	19.2	BD Biosciences	
CEACAM-1		Mouse IgG	-	M. López-Botet (IMIM)	IF
IgA	Biotin	Goat IgG	-	Southern Biotech	IF
IgD	FITC	Goat IgG F(ab') <sub>2</sub>	-	Southern Biotech	FC/IF

IgD	Biotin	Goat IgG F(ab') <sub>2</sub>	-	Southern Biotech	IF
IL-10	PE	Mouse IgG1	JES3-19F1	Biologend	IF
LPS		Mouse IgG2b	2D7/1	Abcam	IHC/IF
MHC-I	PE	Mouse IgG2a	3F10	Ancell	FC
MHC-II	PE	Mouse IgG1	TDR31.3	Ancell	FC
Myeloperoxidase	FITC	Mouse IgG1	F0714	Dako	IF
Neutrophil Elastase		Mouse IgG1	NP57	Dako	IF
Neutrophil Elastase		Rabbit IgG	-	Abcam	IF
Pax-5		Rabbit IgG	-	Neomarkers	IF
vWF		Rabbit IgG	-	Dako	IF

### b. Antibodies to mouse antigens.

Antigen	Label	Isotype	Clone (if monoclonal)	Manufacturer	Use
IgD	FITC	Rat IgG2a	11-26c.2a	BD Biosciences	<sup>¶</sup> IF
IgD	Biotin	Mouse-IgG2b	AMS 9.1	BD Biosciences	IF
MOMA-1	Biotin	Rat IgG2a	MOMA-1	Abcam	IF
Ly6G	Cy5	Rat IgG2b	RB6-8C5	Abcam	IF
Ly6G	APC	Rat IgG2b	RB6-8C5	eBioscience	<sup>#</sup> FC
CD11b	PE	Rat IgG2b	M1/70	eBioscience	FC

<sup>¶</sup>IF, immunofluorescence.

<sup>#</sup>FC, flow cytometry.

\*IHC, immunohistochemistry.

**Table S5. Coating strategy for ELISA.**

<b>Purified antigens</b>	<b>Source</b>	<b>Company</b>	<b>Antigen concentration or dilution</b>
LPS	<i>Escherichia coli</i>	InvivoGen	10 µg/ml
LPS	<i>Pseudomonas aeruginosa</i>	Sigma	1 µg/ml
CPS (serotypes 9N, 14, 19F, 23F)	<i>Pneumococcus</i>	ATCC <sup>s</sup>	10 ng/ml
Gal-α-1,3-Gal		Dextra Lab	0,5 µg/ml
LTA	<i>Bacillus subtilis</i>	Sigma	1 µg/ml
PGN	<i>Bacillus subtilis</i>	Sigma	1 µg/ml
Tetanus toxin	<i>Clostridium tetani</i>	Sigma	0.1 µg/ml
<b>Whole Bacteria</b>			
<i>Escherichia coli</i>		Invitrogen	1:1000*
<i>Salmonella typhimurium</i>		G. Dougar	1:1000
<i>Staphylococcus aureus</i>		ATCC	1:1000
<i>Haemophilus influenzae</i> type-b		ATCC	1:1000
<i>Lactobacillus plantarum</i>		ATCC	1:1000
<b>Vaccines</b>			
Anatoxal Tedi (TT <sup>#</sup> + DT <sup>¶</sup> )		Berna Biotech	1:1000
Menjugate Kit (Meningococcal CPS conjugated with DT)		Novartis	1:1000

<sup>s</sup>ATCC, American Type Culture Collection.

\*Volume:volume.

<sup>#</sup>TT, tetanus toxin.

<sup>¶</sup>DT, diphtheria toxin.

**Table S6. Primers used in RT-PCR and qRT-PCR.**


Target gene		Primer sequence
<i>ACTB</i>	S	GGATGCAGAAGGAGATCACT
	AS	CGATCCACACGGAGTACTTG
<i>AICDA</i>	S	AGAGGCGTGACAGTGCTACA
	AS	TGTAGCGGAGGAAGAGCAAT
<i>ALDH1A1</i>	S	ATGGCATGATTCAGTGAGTG
	AS	GCAGACGATCTCTTTTCGATT
<i>APAF1</i>	S	GTCTGCTGATGGTGCAAG GA
	AS	GATGGCCCGTGTGGATTTC
<i>ARG1</i>	S	ATGGGGACCTGCCCTTTGCT
	AS	CTTCTGCCACCTTGCCAGCC
<i>BAD</i>	S	AGCCAACCAGCAGCAGCCATCAT
	AS	CTCCCCCATCCCTTCGTCGTC
<i>BAK1</i>	S	AGCAGCACCATGGGGCAGGT
	AS	CTCTCAAACAGGCTGGTGGCAATC
<i>BAX</i>	S	AGAGGATGATTGCCGCCGT
	AS	CAACCACCCTGGTCTTGGATC
<i>BCL2</i>	S	CCTCCCTGGCCTGAAGAAGA
	AS	TGTCCTTCGGCGTGGAAATC
<i>BCL2L1</i>	S	GGAAAGCGTAGACAAGGAGATGC
	AS	TCCACAAAAGTATCCCAGCCG
<i>BCL2L11</i>	S	ATGAGAAGATCCTCCCTGCT
	AS	AATGCATTCTCCACACCAGG
<i>BCL10</i>	S	GAACTCCTGGACTCAAGCAA
	AS	GGTGGCTCGTGTCTGTAATC
<i>CARD6</i>	S	GATGACCCAGAGCACGTTGGA
	AS	TCCTCCTCCAATGAAAGGCTGGT
<i>CARD8</i>	S	CTGCCGAGACGGGACAGTGGA
	AS	ATTTGTCACACAGGCCTCAGCCT
<i>CASP1</i>	S	TCTTCCTTTCCAGCTCCTCAGGCA
	AS	TGAGAGCAAGACGTGTGCGGCT
<i>CASP3</i>	S	GCAGCAAACCTCAGGGAAAC
	AS	TGTCGGCATACTGTTTCAGCA
<i>CASP5</i>	S	CCTGCAAGGAATGGGGCTCACTAT
	AS	CTCTGCAGGCCTGGACAATGATGAC
<i>CCL2</i>	S	CCCCAAGCAGAAGTGGGTTC
	AS	TGTCTGGGGAAAGCTAGGGG
<i>CCL3</i>	S	GACTTCAGAAGGACACGGGC
	AS	TGAGCAGGTGACGGAATGTG
<i>CCL4</i>	S	CTGGGTCCAGGAGTACGTGT
	AS	AGGAACTGCGGAGAGGAGTC
<i>CCL5</i>	S	TGAGCTCTGGCTTTGCCTTG
	AS	TCCTCCCCTCCTTGCCTCTA
<i>CCL19</i>	S	CGCCGCAGCAGTTAACCTAT
	AS	CCTTCCTTCTGGTCCTCGGT
<i>CCL20</i>	S	GAACCTTGCTGGGGTTGGAG
	AS	TGGACAAGTCCAGTGAGGCA
<i>CCL21</i>	S	CTGGTTCTGGCCTTTGGCAT




	AS	AAGCTTGGTTCCTGCTTCCG
<i>CD40LG</i>	S	GCTTTGAAATGCAAAAAGGTGAT
	AS	TTGTTTTACTGCTGGCCTCACTT
<i>CXCL1</i>	S	GCGCCCAAACCGAAGTCATA
	AS	TCAGGAACAGCCACCAGTGA
<i>CXCL2</i>	S	AGAAAGCTTGTCTCAACCCCG
	AS	TCCTTCAGGAACAGCCACCA
<i>CXCL3</i>	S	GCGCCCAAACCGAAGTCATA
	AS	TCAGTTGGTGTCTCCCCTTGT
<i>CXCL5</i>	S	TGCTGTGTTGAGAGAGCTGC
	AS	TTGGAGCACTGTGGGCCTAT
<i>CXCL10</i>	S	TGAGCCTACAGCAGAGGAA
	AS	TACTCCTTGAATGCCACTTAGA
<i>CXCL12</i>	S	ACCGCGCTCTGCCTCA
	AS	CATGGCTTTCGAAGAATCGG
<i>CXCL13</i>	S	GCAGCCTCTCTCCAGTCCAA
	AS	TGGACACATCTACACCTCAAGCTT
<i>CRLF2</i>	S	GGGGCAAGGAGGAGCAGATTCA
	AS	GTCGTCTCGCTGCTCTGCGT
<i>FAS</i>	S	ATGCTGGGCATCTGGACCCT
	AS	GCCATGTCCTTCATCACACAA
<i>FASLG</i>	S	TGTGCCCAGAAGGCCTGGTC
	AS	AGGCCTGTGCTGTGGTTCCT
<i>GRN</i>	S	AAGGAGAACGCTACCACGGA
	AS	CGGGACAGCAGTGTATGTGG
<i>ELANE</i>	S	GCGTGGCGAATGTAAACGTC
	AS	CCGTTTTTCGAAGATGCGCTG
<i>IFNA2</i>	S	GTGACCTACCACAAACCCACAGCC
	AS	ATTCTCCTCATCTGCGCCAGGA
<i>IFNG</i>	S	CTAATTATTCGGTAACTGACTTGA
	AS	ACAGTTCAGCCATCACTTGGA
<i>IDO1</i>	S	TGTCTGGCTGGAAAGGCAAC
	AS	CAGCAGGACGTCAAAGCACT
<i>IL1B</i>	S	TCCCCAGCCCTTTTGTGTA
	AS	TTAGAACCAAATGTGGCCGTG
<i>IL6</i>	S	GGTACATCCTCGACGGCATCT
	AS	GTGCCTCTTTGCTGCTTTCAC
<i>IL8</i>	S	CCAAACCTTTCCACCC
	AS	ACTTCTCCACAACCCT
<i>IL10</i>	S	ACCTGCCTAACATGCTTCGAG
	AS	TGTCCAGCTGATCCTTCATTTG
<i>IL10RA</i>	S	TCAGACGCTCATGGGACAGA
	AS	ATACCTCAGGAGCGCCACTT
<i>IL10RB</i>	S	ATCAGGGCAGCAAACAAGGG
	AS	TCTGGTGGCTAAGTCCAGGG
<i>IL12A</i>	S	TTCACCACTCCCAAACCTGC
	AS	GAGGCCAGGCAACTCCCATTAG
<i>IL12B</i>	S	GGGAACTGAAGAAAGATGTTTATG
	AS	CTCTGGTCCAAGGTCC
<i>IL15</i>	S	GTTACCCCCAGTTGCAAAGTAAC

	AS	TATCATGAATACTTGCATCTCCGGA
<i>IL17A</i>	S	CCCCAGTTGATTGGAAGAAA
	AS	GAGGACCTTTTGGGATTGGT
<i>IL18</i>	S	CCAGTGCATTTTGCCCTCCT
	AS	GTTTGTGCGAGAGGAAGCG
<i>IL21</i>	S	TGTGAATGACTTGGTCCCTGAA
	AS	CAGGAAAAAGCTGACCACTCA
<i>IL22</i>	S	GCAGGCTTGACAAGTCCAAC
	AS	GCCTCCTTAGCCAGCATGAA
<i>MCL1</i>	S	GGTACCTTCGGGAGCAGGCCA
	AS	AAGGCCGTCTCGTGGTTGC
<i>MIR155HG</i>	S	CTCTAATGGTGGCACAAA
	AS	TGATAAAAAACAAACATGGGCTTGAC
<i>MPO</i>	S	ATCGGTACCAGCCCATGGAA
	AS	TGACGATTCAGCTTGGCAGG
<i>NLRC4</i>	S	TCCCCGTGCGTCATCGGTGGA
	AS	AGTCAGCAGGGTTCTGGGCAAGG
<i>NLRP3</i>	S	AAAGAGATGAGCCGAAGTGG
	AS	TTCCTGGCATATCACAGTGG
<i>NOS2</i>	S	CCCAGCACAAAGGGAGTGCGG
	AS	AGGATGTCCTGAACATAGACCTTGGG
<i>PAX5</i>	S	TTGCTCATCAAGGTGTCAGG
	AS	CTGATCTCCAGGCAAACAT
<i>PPBP</i>	S	TGTATGCTGAACTCCGCTGC
	AS	TGCAATGGGTTTCCTTCCCG
<i>PRDM1</i>	S	GTGGTATTGTCGGGACTTTGCAG
	AS	TCGGTTGCTTTAGACTGCTCTGTG
<i>PTX3</i>	S	GGGACAAGCTCTTCATCATGCT
	AS	GTCGTCCGTGGCTTGCA
<i>SLPI</i>	S	CCTGGATCCTGTTGACACCC
	AS	CACTTCCCAGGCTTCCTCCT
<i>SOCS1</i>	S	CGATTACCGGCGCATCACGC
	AS	TGTCGCGCACCAGGAAGGTG
<i>SOCS3</i>	S	CACTCTTCAGCATCTCTGTCGGAAG
	AS	CATAGGAGTCCAGGTGGCCGTTGAC
<i>TGFB1</i>	S	AAGGACCTCGGCTGGAAGTGG
	AS	CCGGGTTATGCTGGTTGTA
<i>TNF</i>	S	CCCAGGCAGTCAGATCATCTTC
	AS	AGCTGCCCCCTCAGCTTGA
<i>TNFSF13</i>	S	GAAGGCAGGAGACTCTATTCCG
	AS	CCCTTGGTGTAATGGAAGAC
<i>TNFSF13B</i>	S	ACCGCGGGACTGAAAATCT
	AS	CACGCTTATTTCTGCTGTTCTGA
<i>TSLP</i>	S	CCCAGGCTATTCGGAAACTCAG
	AS	CGCCACAATCCTTGTAATTGTG
<i>TLR1</i>	S	GGCTGGCCTGATTCTTATAAGTG
	AS	CTCTAGGTTTGGCAATAATTCATTC
<i>TLR2</i>	S	CAGCAGGTTTCAGGATGTCCG
	AS	GCAGATGTTCCCTGCTGGGAG
<i>TLR3</i>	S	TGACTGAACTCCATCTCATGTCC

	AS	CCATTATGAGACAGATCTAATGTG
<i>TLR4</i>	S	CCCTGCGTGGAGGTAT
	AS	GCACCTGCAGTTCTGGGAAA
<i>TLR6</i>	S	AAGCGGAGGTTCTAGGCCAT
	AS	CTGCACTGAACCTGTGTGCT
<i>TLR7</i>	S	GCTGTGACCGAGTGGGTTTT
	AS	TTTTCCAGAACTGGCTGCCC
<i>TLR8</i>	S	TTCCTGTGAGTTATGCGCCG
	AS	TATTTGCCACCGTTTGGGG
<i>TLR9</i>	S	ACAACAACATCCACAGCCAAGTGTC
	AS	AAGGCCAGGTAATTGTCACGGAG
<i>XBPI</i>	S	AGGAGTTAAGACAGCGCTTGG
	AS	AGAGGTGCACGTAGTCTGAGTGCTG
<i>I6SrRNA</i>	S	TGGTGTGTAATAATGTTCTCGTCAA
	AS	TTCGTATTACCGCGGCTGCTGG
<i>V<sub>H</sub>3-23</i>	S	GGCTGAGCTGGCTTTTTCTTGTGG
	AS <sub>μ</sub>	GTTGCCGTTGGGGTGCTGGAC
	AS <sub>γ</sub>	AAGACCGATGGGCCCTTGGTGG
<i>intV<sub>H</sub>3-23</i>	S	GGGGTCCCTGAGACTCTC
	AS <sub>μ</sub>	AAGGAAGTCCTGTGCGAGGCAGC
	AS <sub>γ</sub>	AAGACCGATGGGCCCTTGGTGG




**Figure S1. Neutrophils colonize perifollicular areas of mesenteric lymph nodes.** Immunohistochemistry of tonsil (TON), intestinal Peyer's patches (PP) and mesenteric lymph node (MLN) stained for CD20 (brown) and myeloperoxidase (MPO, red). Boxes correspond to magnified right images. Original magnification, x4 (left) and x20 (right). Data are from one of five experiments with similar results.




**Figure S2. Perifollicular neutrophils colonize spleens that have no histological alterations. (a)**

Light microscopy of normal spleens stained with hematoxylin and eosin (H&E). Original magnification, x4. **(b)** Immunofluorescence of spleens stained for elastase (ELA, green), CD15, myeloperoxidase (MPO), CD11c, CD68, CD163 or mouse IgG1 isotype control (red), and IgD (blue). MZ, marginal zone; PFA, perifollicular area; RP, red pulp; GC, germinal center; FM, follicular mantle. Original magnification, x10. Data are from one of five experiments with similar results.






**Figure S3. Neutrophils selectively colonize splenic perifollicular areas in healthy humans, rhesus macaques and mice, but invade splenic follicular areas in patients with systemic inflammation or infection.** (a) Immunofluorescence of normal rhesus macaque spleen (left panel), and normal mouse spleen (right panel) stained for elastase (ELA) or Ly6G (green), MR or MOMA-1 (red), and IgD (blue). Original magnification, x10. (b) Immunofluorescence of spleens stained for ELA (green), MR (red), and IgD (blue) from individuals with (right panels) or without (left panels) systemic inflammation or infection, including hyper-IgD syndrome (HIDS), HIV infection, systemic lupus erythematosus (SLE), and sepsis. Original magnification, x10. Data are from one of several experiments with similar results.




**Figure S4. Neutrophil presence in spleens and mesenteric lymph nodes correlates with a higher percentage of MZ B cells.** (a) Flow cytometry of neutrophils from peripheral lymph node (PLN), tonsil (TON), spleen (SPL) and mesenteric lymph node (MLN) cells. Oval gate includes cells with size (forward scatter, FSC) and intracellular complexity (side scatter, SSC) compatible with those of neutrophils. Numbers indicate percentage of neutrophils. (b) Light microscopy (first and third panels from left) and transmission electron microscopy (second and fourth panels from left) of neutrophils from peripheral blood (PB) and spleen (SPL) of healthy donors. Original magnification, x63 (Giemsa) and x790 (electron microscopy). (c) Flow cytometry of IgD and CD27 on CD19-gated B cells from PLN, TON, SPL, MLN. Data are from one of five experiments with similar results.




**Figure S5. N<sub>BH</sub> cells show better short-term survival but equivalent long-term survival as compared to N<sub>C</sub> cells and activate MZ B cells via both contact-dependent and contact-independent mechanisms.** (a) Flow cytometry of viable annexin V-negative propidium iodide-negative N<sub>C</sub> and N<sub>BH</sub> cells after 18 h of culture with medium alone (left panel) or after co-culture with MZ B cells for 7d (right panel). (b) ELISA of IgM from splenic MZ B cells cultured with N<sub>BH</sub> or N<sub>BH</sub> conditioned medium (N<sub>BHcm</sub>). N<sub>BH</sub> cells were primed with medium or LPS. Error bars, s.e.m.; \* P < 0.05 (one-tailed unpaired Student's t-test). Data are from one of three experiments with similar results.






**Figure S6. N<sub>BH</sub> but not N<sub>C</sub> cells induce more AID and more IgG and IgA in MZ than FN B cells.** (a) qRT-PCR of *AICDA* mRNA (encoding AID) from splenic follicular naïve (FN), MZ and germinal center (GC) B cells isolated from two healthy donors. Results are normalized to *ACTB* mRNA (encoding  $\beta$ -actin) and are presented as relative expression (RE) compared with that of FN B cells. (b) qRT-PCR of *AICDA* mRNA from splenic MZ and FN B cells cultured for 2 d with medium (Ctrl), N<sub>C</sub> cells or N<sub>BH</sub> cells. Results are normalized to *PAX5* mRNA (encoding the B cell protein Pax5) and are presented as RE compared with that of FN B cells or MZ B cells incubated with medium alone. (c) IgG and IgA from splenic MZ and FN B cells cultured as in a for 4 d. Error bars, s.e.m.; \*  $P < 0.005$  (one-tailed unpaired Student's t-test). Data are from one of five experiments with similar results (a) or summarize three independent experiments (b,c).




**Figure S7.  $N_{BH1}$  and  $N_{BH2}$  cells have comparable morphological and ultrastructural features.**

(a) Flow cytometry of  $N_{BH}$  (top panels) and  $N_C$  cells (bottom panels) gated according to canonical forward scatter (FSC) and side scatter (SSC) parameters and negativity for DAPI. (b and c) Light microscopy (b) and transmission electron microscopy (c) of  $N_{BH1}$  (left panels) and  $N_{BH2}$  (right panels) cells from healthy donors. Original magnification, x63 (Giemsa) and x790 (electron microscopy). Data are from one of several experiments with similar results.




**Figure S8. Inflamed splenic tissue contains  $N_{BH1}$  but not  $N_{BH2}$  cells.** Flow cytometry of CD15, CD16, CD24, CD11b, CD86, CD95, HLA-I, HLA-II, CD54, CD102, CD62L and CD62P on  $N_{BH}$  cells from the spleen of a patient with hyper-IgD syndrome (HIDS). Gray solid profile, isotype control. Data are from one of four experiments with inflamed spleens from patients affected with HIDS, HIV, lupus or sepsis that yielded similar results.




**Figure S9.**  $N_{BH1}$  and  $N_{BH2}$  cells express more mRNAs for B cell activation, B cell recruitment, immune activation, immune regulation and cell survival molecules than  $N_C$  cells. Gene expression profile of  $N_C$ ,  $N_{BH1}$  and  $N_{BH2}$  cells established by customized qRT-PCR arrays. Results are normalized to *ACTB* mRNA (encoding  $\beta$ -actin) and are presented as relative expression (RE)

compared with that of N<sub>C</sub> cells. Functional mRNA clusters and highly relevant mRNAs are indicated. *TNFSF13B*, *TNFSF13*, *NLRP3*, *IL1B*, *IL12A*, *IL10RA*, *IL10RB*, *ARG1*, *ALDH1A1*, *IDO1*, *NOS2*, *GRN* *SLPI*, and *BCL2L1* mRNAs encode BAFF, APRIL, NALP-3, IL-1 $\beta$ , IL-12p35, IL-10 receptor  $\alpha$ , IL-10 receptor  $\beta$ , arginase I, RALDH, IDO, iNOS, progranulin, SLPI and bcl-xL, respectively. Error bars, s.e.m. Data summarize three independent experiments.




**Figure S10.  $N_{BH}$  express mRNA for CD40L, although less than splenic  $CD4^+$  T cells.** qRT-PCR of mRNA for CD40L in  $N_{BH}$  cells, splenic macrophages ( $M_s$ ), splenic dendritic cells ( $DC_s$ ), circulating dendritic cells ( $DC_c$ ), and splenic  $CD4^+$  T cells ( $T_s$ ). Results are normalized to *ACTB* mRNA (encoding  $\beta$ -actin) and are presented as relative expression (RE) compared with that of  $DC_s$  cells. Data are from one of two experiments with similar results.




**Figure S11.  $N_{BH}$  but not  $N_C$  cells spontaneously form NET-like structures.** Confocal microscopy of  $N_C$  and  $N_{BH}$  cells stained for elastase (ELA, green) and DNA (blue). Original magnification, x40 (first two rows and fourth row from top) and x63 (third row from top). Data are from one of three experiments with similar results.






**Figure S12.**  $N_{BH2}$  cells are more apoptotic than  $N_{BH1}$  cells and may correspond to apoptotic  $N_{BH}$  cells occupying splenic peri-MZ areas. (a) Flow cytometric analysis of annexin V on  $N_{BH1}$  and  $N_{BH2}$  cells. (b) Immunofluorescence of spleen processed for TUNEL assay (green) and co-stained for elastase (ELA, red). The same image is shown in Fig. 3d at smaller magnification. FO, follicle. Original magnification,  $\times 10$ . Data are from one of three experiments with similar results.






**Figure S13. Control antibodies isotype-matched with antibodies reactive for BAFF and APRIL do not stain splenic peri-MZ areas.** Fluorescence microscopy of spleens stained for control mouse IgG1 (Ctrl1) or control rabbit IgG (Ctrl2) antibodies (red) and DNA (blue). Original magnification, x10. Data are from one of three experiments with similar results.




**Figure S14.  $N_{BH}$  cells are proximal to SECs and macrophages producing IL-10.** (a) Immunofluorescence of spleen stained for elastase (ELA, green), CD31, von Willebrand factor (vWF) or MR (red), and IgD (blue). Original magnification, x10 (left and mid panels) and x63 (right panel). (b) Flow cytometry of CD8, CD31, and MR on SECs. Red circle gates SECs expressing CD8 and CD31. Gray profile, isotype control. (c) Immunofluorescence of SECs stained for CD31 DNA and vWF DNA. (d) Bar graph of IL-10 production. (e) Immunofluorescence of SECs stained for ELA CD68 Ctrl and ELA CD68 IL-10. NBH,  $N_{BH}$  cells; SEC, splenic endothelial cells; M, macrophages.


for CD31 or vWF (red) and DNA (blue). Original magnification, x40. **(d)** ELISA of IL-10 from SECs incubated with medium (Ctrl) or LPS for 24 h. **(e)** Immunofluorescence of SECs stained for ELA (green), CD68 (red), and IL-10 or control mouse IgG1 antibody isotype-matched with the anti-IL-10 antibody (blue). Dashed area corresponds to magnified left-bottom image. Arrowheads point to SEC, N<sub>BH</sub> and macrophage (M). Original magnification, x40. Error bars, s.e.m.; \*  $P < 0.05$  (one-tailed Student's t-test). Data are from five **(a-c)** of three **(e)** experiments with similar results or summarize three independent experiments **(d)**.




**Figure S15. N<sub>C</sub> cells acquire N<sub>BH</sub>-like properties in response to either pro-apoptotic or anti-apoptotic activating signals.** (a) Flow cytometric analysis of viable annexin V-negative propidium iodide-negative N<sub>C</sub> cells cultured for 18 h in the presence of medium (Ctrl), LPS, IL-10, zymosan or GM-CSF. (b) qRT-PCR of *TNFSF13* encoding APRIL in N<sub>C</sub> cells cultured as in a. Results are normalized to *ACTB* mRNA (encoding  $\beta$ -actin) and presented as relative expression (RE) compared with that of unstimulated cells. (c) qRT-PCR of *AICDA* encoding AID in circulating unswitched IgD<sup>+</sup> B cells cultured for 2 d with N<sub>C</sub> cells stimulated as in a. Results are normalized to *PAX5* mRNA and presented as RE compared with that of B cells cultured with unstimulated N<sub>C</sub> cells. Error bars, s.e.m. Data summarize three independent experiments.



**Figure S16.  $iN_{BH}$  cells express more CD24 regulatory protein but less CD62L adhesion protein than  $N_C$  cells.** Flow cytometry of  $iN_{BH}$  cells (red profile) obtained 4 h after trans-SEC migration and control non-transmigrated  $N_C$  cells (blue profile). Data are from one of three experiments with similar results.




**Figure S17. SECs enhance the production of neutrophil-attracting chemokines in response to microbial signals. (a)** ELISA of IL-8 (CXCL8) from SECs cultured with medium alone (Ctrl) or LPS for 12 h. **(b)** qRT-PCR of mRNA for CXCL1, CXCL2, CXCL3 and CXCL6 from SECs exposed to LPS for 0, 1, 6, 12, 24 or 48 h. Error bars in **a** panel, s.e.m. Data summarize three independent experiments **(a)** or represent one of three experiments with similar results **(b)**.




**Figure S18. Neutropenia and functional neutrophil disorders decrease preimmune serum concentrations of IgM, IgG and IgA to TI antigens. (a) ELISA for IgM, IgG and IgA to LPS from Escherichia coli in serum of age-matched healthy donors (HD) and a subset of patients with**

neutrophil disorders (ND) but numerically conserved circulating MZ B cells. OD, optical density. SCN, severe congenital neutropenia; SBDS, Shwachman-Bodian-Diamond syndrome; WHIM, warts-hypogammaglobulinemia-infections-myelokatexis syndrome; CN, cyclic neutropenia; CGD, chronic granulomatous disease; LAD-1, leukocyte adhesion deficiency-1. *ELANE*, *WASP*, *SBDSP1*, *CXCR4*, *CYBB* and *ITGB2* indicate genes encoding elastase, Wiskott-Aldrich syndrome protein, SBDS protein 1, CXCR4, p91-PHOX and CD18, respectively. **(b)** ELISA for IgM, IgG and IgA to LPS from *Pseudomonas aeruginosa*, CPS from *Pneumococcus* 9N, 14, 19F and 23F, Gal- $\alpha$ -1,3-Gal (or  $\alpha$ -Gal), tetanus toxin (TT) combined with diphtheria toxin (DT), and CPS from *Meningococcus* conjugated with DT in serum of patients with ND as in **a** and age-matched HD. OD, optical density. Error bars, median and percentile 25 and 75; \*  $P < 0.05$  (Mann-Whitney U test).






**Figure S19.** N<sub>BH</sub> cells induce MZ B cell secretion of IgM, IgG and IgA to TI antigens. ELISA for IgM, IgG and IgA to LPS from Escherichia coli and to LTA and PGN from Bacillus subtilis in splenic MZ B cells cultured with medium alone (Ctrl) or N<sub>BH</sub> cells for 6 d. OD, optical density. One of three experiments with similar results.




**Figure S20. Neutropenia and functional neutrophil disorders decrease preimmune serum concentrations of IgM, IgG and IgA to some mucosal bacteria.** ELISA for IgM, IgG and IgA to whole fixed *Haemophilus influenzae* type-b, *Lactobacillus plantarum*, *Salmonella typhimurium*, *Staphylococcus aureus* and *Escherichia coli* in the plasma of patients with neutrophil disorders and age-matched healthy donors. SCN, severe congenital neutropenia; SBDS, Shwachman-Bodian-

Diamond syndrome; WHIM, warts-hypogammaglobulinemia-infections-myelokatexis syndrome; CN, cyclic neutropenia; CGD, chronic granulomatous disease; LAD-1, leukocyte adhesion deficiency-1. *ELANE*, *WASP*, *SBDS*, *CXCR4*, *CYBB* and *ITGB2* indicate genes encoding elastase, Wiskott-Aldrich syndrome protein, SBDS protein 1, CXCR4, p91-PHOX and CD18, respectively. OD, optical density. Error bars, median and percentile 25 and 75; \*  $P < 0.05$  (Mann-Whitney U test).



**Figure S21.  $N_C$  cells from healthy donors and neutropenic patients acquire comparable  $N_{BH}$ -like function in response to IL-10.** ELISA of IgG secreted by circulating unswitched  $IgD^+$  B cells cultured for 7 d with medium alone or IL-10-induced  $iN_{BH}$  cells from healthy donors (HD;  $n = 3$ ) or six patients with severe congenital neutropenia (SCN) caused by unknown molecule defects (unknown;  $n = 3$ ) or deleterious mutations of the gene encoding elastase (*ELANE*;  $n = 3$ ). Error bars, s.e.m.



**Figure S22. Proposed model for  $N_{BH}$  cell reprogramming and function.**  $N_C$  cells home to the spleen under homeostatic conditions in response to microbial products undergoing splenic filtration after systemic translocation from mucosal surfaces. In the presence of TLR signals, SECs release chemokines such as IL-8 to induce recruitment of  $N_C$  cells as well as STAT3-inducing cytokines such as IL-10 to induce reprogramming of  $N_C$  cells into  $N_{BH}$  cells. These latter include  $N_{BH1}$  and  $N_{BH2}$  subsets with distinct phenotype, gene expression profile and B-helper activity.  $N_{BH}$  cells trigger Ig SHM, CSR, plasma cell differentiation (PCD), including IgM, IgG and IgA production, by activating MZ B cells through a mechanism involving BAFF, APRIL and IL-21 release as well as formation of antigen-trapping NET-like structures. Production of B cell-attracting chemokines such as CXCL12 and CXCL13 as well as PCD-inducing cytokines such as IL-6 may also play a role. Interaction of  $N_{BH}$  cells with MZ B cells would facilitate the formation of a circulating pre-immune repertoire of antimicrobial Igs to TI antigens. In addition to activating MZ B cells,  $N_{BH}$  cells suppress splenic  $CD4^+$  T cells through a contact-independent mechanism that might involve IL-10, arginase, IDO, iNOS, RALDH, progranulin and SLPI. This T cell-suppressor activity could enable  $N_{BH}$  cells to sustain tonic TI MZ B cell activation without triggering TD follicular B cell activation and inflammatory tissue damage.

**SUPPLEMENTARY MOVIE LEGENDS**

**Movie S1.  $N_{BH}$  cells form NET-like structures to interact with splenic MZ B cells.** Confocal microscopy and three-dimensional animation of a spleen section stained for elastase (green), IgD (red) and DNA (blue). The movie was generated by acquiring up to 14 x,y planes with 0.3  $\mu\text{m}$  z spacing. Original magnification, x40. One of three experiments yielding similar results.

**Movie S2.  $N_{BH}$  cells spontaneously form DNA-containing NET-like projections.** Confocal microscopy and three-dimensional animation of  $N_{BH}$  cells stained for elastase (green) and DNA (blue). The movie was generated by acquiring up to 25 x,y planes with 0.3  $\mu\text{m}$  z spacing. Original magnification, x63; digital magnification, x2. One of three experiments yielding similar results.